269 related articles for article (PubMed ID: 19006260)
1. Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial.
Chokka P; Legault M
Depress Anxiety; 2008; 25(12):E173-81. PubMed ID: 19006260
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
3. An open-label multicentric study of the tolerability and response to escitalopram treatment in Indian patients with major depressive disorder.
Pinto C; Trivedi JK; Vankar GK; Sharma PS; Narasimha V
J Indian Med Assoc; 2007 Jul; 105(7):364, 366, 368 passim. PubMed ID: 18178988
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
Boulenger JP; Huusom AK; Florea I; Baekdal T; Sarchiapone M
Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
Colonna L; Andersen HF; Reines EH
Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram in patients with major depressive disorder.
Schmitt L; Tonnoir B; Arbus C
Neuropsychobiology; 2006; 54(4):201-7. PubMed ID: 17337913
[TBL] [Abstract][Full Text] [Related]
7. The influence of educational information on depressed outpatients treated with escitalopram: a semi-naturalistic study.
Leinonen E; Niemi H
Nord J Psychiatry; 2007; 61(2):109-14. PubMed ID: 17454725
[TBL] [Abstract][Full Text] [Related]
8. A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety.
Olié JP; Tonnoir B; Ménard F; Galinowski A
Depress Anxiety; 2007; 24(5):318-24. PubMed ID: 17041922
[TBL] [Abstract][Full Text] [Related]
9. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
Bose A; Korotzer A; Gommoll C; Li D
Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245
[TBL] [Abstract][Full Text] [Related]
10. Escitalopram in clinical practice: results of an open-label trial in outpatients with depression in a naturalistic setting in Germany.
Möller HJ; Langer S; Schmauss M
Pharmacopsychiatry; 2007 Mar; 40(2):53-7. PubMed ID: 17447173
[TBL] [Abstract][Full Text] [Related]
11. [Severe forms of depression: the efficacy of escitalopram].
Spadone C
Encephale; 2009 Apr; 35(2):152-9. PubMed ID: 19393384
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of escitalopram in patients with severe depression: a pooled analysis.
Llorca PM; Azorin JM; Despiegel N; Verpillat P
Int J Clin Pract; 2005 Mar; 59(3):268-75. PubMed ID: 15857321
[TBL] [Abstract][Full Text] [Related]
13. A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms.
Fraguas R; da Silva Telles RM; Alves TC; Andrei AM; Rays J; Iosifescu DV; Wajngarten M
Contemp Clin Trials; 2009 May; 30(3):205-11. PubMed ID: 19470312
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
Chauvet-Gélinier JC
Encephale; 2010 Oct; 36(5):425-32. PubMed ID: 21035633
[TBL] [Abstract][Full Text] [Related]
15. Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study.
Pae CU; Kim YJ; Won WY; Kim HJ; Lee S; Lee CU; Lee SJ; Kim DW; Lee C; Min WS; Kim CC; Paik IH; Serretti A
Hum Psychopharmacol; 2004 Jan; 19(1):25-9. PubMed ID: 14716708
[TBL] [Abstract][Full Text] [Related]
16. Superiority of escitalopram to paroxetine in the treatment of depression.
Kasper S; Baldwin DS; Larsson Lönn S; Boulenger JP
Eur Neuropsychopharmacol; 2009 Apr; 19(4):229-37. PubMed ID: 19185467
[TBL] [Abstract][Full Text] [Related]
17. An open-label, flexible-dose study of memantine in major depressive disorder.
Ferguson JM; Shingleton RN
Clin Neuropharmacol; 2007; 30(3):136-44. PubMed ID: 17545748
[TBL] [Abstract][Full Text] [Related]
18. The effect of escitalopram on sleep problems in depressed patients.
Lader M; Andersen HF; Baekdal T
Hum Psychopharmacol; 2005 Jul; 20(5):349-54. PubMed ID: 15912558
[TBL] [Abstract][Full Text] [Related]
19. Effective dose of escitalopram in moderate versus severe DSM-IV major depression.
Bech P; Andersen HF; Wade A
Pharmacopsychiatry; 2006 Jul; 39(4):128-34. PubMed ID: 16871468
[TBL] [Abstract][Full Text] [Related]
20. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
Demyttenaere K; Hemels ME; Hudry J; Annemans L
Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
